Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Salud y medicinaOne-Off3a
Manifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actualSí 78.9%
Pronosticadores
29
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 11 horas
Desactualizado26 ene 24, 0:13 UTC1 ene 30, 7:59 UTC
Tendencias
Reglas
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy.
- Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
- To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein).
- The gene therapy must be for humans.
- Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
